In a study of men on active surveillance for low-risk prostate cancer, multiparametric magnetic resonance imaging by itself missed about one-fifth of men who had pathologic upgrading on subsequent biopsies.
A new analysis looking at the effect of PSA screening on prostate cancer mortality over a 25-year period found a more favorable balance of benefits and harms than the 16-year estimates from the European Randomized Study of Screening for Prostate Cancer.
Three major medical organizations have issued recommendations for the diagnosis and treatment of advanced prostate cancer, including metastatic hormone-sensitive disease and nonmetastatic and metastatic castration-resistant disease.
A study looking at the effect of genetic variations on the pharmacologic activity of metformin found that use of the drug was associated with an increased risk of prostate cancer overall and of high-grade prostate cancer.
Investigators performed a literature review to better understand how delays in treatment might affect clinical outcomes in urologic cancer patients, including the risk of upstaging, recurrence, and mortality.
FDA has approved rucaparib for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer in men previously treated with androgen-receptor directed therapy and taxane-based chemotherapy.
In a retrospective study, addition of carboplatin to chemotherapy regimens improved survival in men with metastatic castration-resistant prostate cancer whose disease progressed on second-generation hormone therapy.
Cytoreductive radical prostatectomy following neoadjuvant androgen-deprivation therapy (ADT) in men with hormone-naïve low-volume metastatic prostate cancer improves survival long-term vs ADT alone, a study found.